CCL2 and mucositis: In diverse experimental models of degenerative and inflammatory diseases including GVHD, chemotherapy-associated mucositis, atherosclerosis, and myocardial, renal, and hepatic ischemia-reperfusion injuries, NecroX-7 decreased the expression of pro-inflammatory cytokines or damage-associated molecular pattern (DAMPs), i.e., TNFα, IL-1R, IL-6, iNOS, MCP-1, or HMGB1 (Im et al., 2015; Grootaert et al., 2016; Jin et al., 2016; Lee et al., 2016; Hwang et al., 2018; Im et al., 2019), in line with our findings of NecroX-7-mediated anti-inflammation.